Durso Jerome Benedict
Transaction: 08/13/2026
BUY
Change
+15,000
Price
$2.95
Filing
08/13/2026
Type
BUY
Altimmune, Inc.
ALT • Biotechnology
$3.42
▲ +0.19 (+5.88%)
Current price
EarningsLatest report: Jun 30, 2026
WEAK PROFILEWeakConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Weak historical ratio profile. The current evidence does not support a favorable risk/reward view.
Market Cap
$634.22M
Growth
-41.7%
Cash Flow
0/5
Trend
Negative
Evidence
Manageable debt level · 0.16Healthy liquidity · 18.55Negative growth trendWeak profitability
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 14, 2026, 12:11 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$3.42
Change5.88%
Shares Out185.44M
Market Cap$634.22M
Enterprise Value$307.94M
52W Range2.56 - 6.44
Beta0.17
P/E-6.91
P/S20,458.63
P/B1.34
P/FCF-8.28
EV/Sales9,933.44
Price$3.42
Change5.88%
Shares Out185.44M
Market Cap$634.22M
Enterprise Value$307.94M
52W Range2.56 - 6.44
Beta0.17
P/E-6.91
P/S20,458.63
P/B1.34
P/FCF-8.28
EV/Sales9,933.44
EV/EBITDA-3.30
EV/FCF-4.02
Earnings Yield-14.47%
FCF Yield-12.07%
Dividend Yield0.00%
Gross Margin100.00%
Oper. Margin-2304.61%
Profit Margin-2148.61%
Debt/Eq0.16
Current Ratio18.55
Quick Ratio18.55
Revenue 5Y-41.66%
Target$6.25
Target Upside82.75%
Target Median$6.25
Target Range2.50 - 10.00
Volume3.88M
Avg Volume4.19M
EPS Surprise0.07
Investment DNA
How strong this company looks for long-term investors
35
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
76/100
Growth Potential
Revenue and expansion
20/100
Price Attractiveness
Cheap or expensive today
56/100
Why this score▼
Manageable debt level · 0.16Healthy liquidity · 18.55Negative growth trendWeak profitability
Analyst view
Analyst sentiment and price target
Analyst sentiment
Based on 15 analyst votes · 2026-09-05
90/100
Bullish
Bullish
12
Hold
3
Bearish
0
Price Target
2026-08-14
Low
$2.50
Mean
$6.25
Median
$6.25
High
$10.00
Insider Transactions
Recent executive and insider activity
Roberts M Scot
Transaction: 07/31/2026
BUY
Change
+875
Price
$2.41
Filing
08/03/2026
Type
BUY
WEAVER GREGORY L
Transaction: 07/31/2026
BUY
Change
+1,753
Price
$2.41
Filing
08/03/2026
Type
BUY
| Insider | Type | Change | Price | Transaction | Filing |
|---|---|---|---|---|---|
| Durso Jerome Benedict | BUY | +15,000 | $2.95 | 08/13/2026 | 08/13/2026 |
| Roberts M Scot | BUY | +875 | $2.41 | 07/31/2026 | 08/03/2026 |
| WEAVER GREGORY L | BUY | +1,753 | $2.41 | 07/31/2026 | 08/03/2026 |
| SAYARE MITCHEL | BUY | +48,800 | $2.82 | 05/01/2026 | 05/01/2026 |
| GILL JOHN | BUY | +48,800 | $2.82 | 05/01/2026 | 05/01/2026 |
| Hodges Philip | BUY | +48,800 | $2.82 | 05/01/2026 | 05/01/2026 |
| Pisano Wayne | BUY | +48,800 | $2.82 | 05/01/2026 | 05/01/2026 |
| Schafer Klaus | BUY | +48,800 | $2.82 | 05/01/2026 | 05/01/2026 |
| Jorkasky Diane | BUY | +48,800 | $2.82 | 05/01/2026 | 05/01/2026 |
| Sohn Catherine A. | BUY | +48,800 | $2.82 | 05/01/2026 | 05/01/2026 |
| Lawver Teri L | BUY | +48,800 | $2.82 | 05/01/2026 | 05/01/2026 |
| GILL JOHN | BUY | +9,200 | $3.41 | 04/06/2026 | 04/06/2026 |
| Durso Jerome Benedict | BUY | +15,000 | $3.14 | 04/01/2026 | 04/01/2026 |
| WEAVER GREGORY L | BUY | +10,000 | $3.15 | 04/01/2026 | 04/01/2026 |
| Durso Jerome Benedict | BUY | +20,000 | $3.54 | 03/06/2026 | 03/09/2026 |
| WEAVER GREGORY L | BUY | +5,000 | $3.54 | 03/06/2026 | 03/09/2026 |
| WEAVER GREGORY L | BUY | +111,000 | Not reported | 02/26/2026 | 02/27/2026 |
| WEAVER GREGORY L | BUY | +259,000 | $4.46 | 02/26/2026 | 02/27/2026 |
| Roberts M Scot | BUY | +95,430 | Not reported | 02/26/2026 | 02/27/2026 |
| Roberts M Scot | BUY | +222,670 | $4.46 | 02/26/2026 | 02/27/2026 |